NYSE Flags Annovis for Listing Non-Compliance as Market Cap Slips Below $50M
ANVS sits 24% above its 52-week low of $0.93.
Summary
Annovis received an NYSE notice on October 29 that it fails Section 802.01B: its 30 trading-day average market cap was about $48.4 million against a $50 million threshold, and its last reported stockholders' deficit was roughly $(4.3) million as of June 30, 2026. The stock keeps trading under ANVS but now carries a '.BC' designation until compliance is regained. The company has 45 days to submit a cure plan and up to 9 months to execute it; if the NYSE rejects the plan or the company misses the cure, delisting proceedings begin. This lands on top of an already thin balance sheet — Q2 showed a $0.40 per share net loss and $18.7 million in cash — and a pending November 3 special meeting to double authorized shares to 140 million, which is the most obvious lever to fix the equity deficit. The NYSE can accelerate delisting if the stock trades at abnormally low levels, generally below $0.10; at $1.15 there is room, but the equity hole is the harder problem.
At the time of this announcement, ANVS was trading at $1.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $48.2M. The 52-week trading range was $0.93 to $5.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.